The U.S. Food and Drug Administration (FDA) approved a new drug, anifrolumab (Saphnelo), for moderate to severe systemic lupus erythematosus (SLE). This is the first type 1 interferon receptor antagonist for lupus.
Gradually weaning off steroids may lead to less flares among lupus patients in remission than staying on a low-dose treatment, new research found.
A new study shows that lupus patients who need to take hydroxychloroquine can be reassured that it does not have a significant risk for serious heart toxicity.
In a recent study, 86 percent of people with lupus and 72 percent of rheumatologists treating lupus agreed that having people fill out short surveys about fatigue, pain, and more helped improve communication.
The findings highlight the importance of conversations between doctors and patients about drug costs.
Anifrolumab will seek FDA approval.
Omalizumab might help target inflammation in lupus patients and help improve disease activity.